Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009;11 Suppl 3(Suppl 3):S7.
doi: 10.1186/bcr2426. Epub 2009 Dec 18.

Tailored targeted therapy for all: a realistic and worthwhile objective?

Per Eystein Lønning  1
Affiliations

Tailored targeted therapy for all: a realistic and worthwhile objective?

Per Eystein Lønning. Breast Cancer Res. 2009.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Classes of breast cancer based on gene expression profiles. Gene expression pattern of 85 experiment samples representing 78 carcinomas, three benign tumours and four normal tissues. Basal, basal-like cell class; HER2, HER2 class; Nor, normal cell-like class; LUM B A, luminal B and luminal A classes, respectively. Note: in the initial work light blue was termed luminal C class while yellow was luminal B - these two classes together now are grouped as luminal B. Adapted from [9].
See this image and copyright information in PMC

References

    1. Lønning PE, Knappskog S, Staalesen V, Chrisanthar R, Lillehaug JR. Breast cancer prognostication and prediction in the postgenomic era. Ann Oncol. 2007;18:1293–1306. doi: 10.1093/annonc/mdm013. - DOI - PubMed
    1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182. doi: 10.1126/science.3798106. - DOI - PubMed
    1. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–1684. doi: 10.1056/NEJMoa052122. - DOI - PubMed
    1. Lønning PE, Sørlie T, Børresen-Dale A-L. Genomics in breast cancer - therapeutic implications? Nat Clin Pract Oncol. 2005;2:26–33. doi: 10.1038/ncponc0072. - DOI - PubMed
    1. Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdottir K, Olsen KE, Mouridsen H, Ejlertsen B. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol. 2005;23:7483–7490. doi: 10.1200/JCO.2005.11.007. - DOI - PubMed

MeSH terms